CAR T-Cell Therapy: The Next Frontier for Cancer Immunotherapy

R. Tamhane,Siddhesh Warke

Abstract:Cancer is among the leading cause of death around the world. Till now many different types of therapies, medications have been developed for these neoplastic diseases. But due to their restricted effectiveness in accordance with the heterogeneity of cancer cells, there is a constant need for novel therapeutic approaches with improved success, like an immunotherapy that uses and enhances the capacity of the patient’s immune system. Chimeric antigen receptor T cells are T cells that are genetically modified to produce an artificial T cell receptor to target a specific protein. The chimeric antigen receptors are called so as they have both antigen binding and T cell activating functions on a single receptor. CAR T cell therapy uses T cells engineered with CARs for cancer treatment. In this review, we will discuss the basic design of CARs, the different FDA approved CAR T cell therapies in preventing different types of cancer, the factors affecting the therapy and the risks involved around the therapy. Index Terms Chimeric antigen receptors, CAR T cell therapy, Cancer Immunotherapy, tumor, FDA approved therapy.

Medicine